Analyst Reco. Health Catalyst, Inc.

Equities

HCAT

US42225T1079

Real-time Estimate Cboe BZX Other stock markets 17:39:33 06/05/2024 BST			5-day change	1st Jan Change
6.69 ^USD	+3.24%		+5.36%	-27.86%

04-11	North American Morning Briefing : Stock Futures -2-	DJ
04-10	KeyBanc Downgrades Health Catalyst to Sector Weight From Overweight on Potential Risks to Hospital End Markets	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

KeyBanc Downgrades Health Catalyst to Sector Weight From Overweight on Potential Risks to Hospital End Markets	04-10	MT
KeyBanc Cuts Price Target on Health Catalyst to $10 From $12, Keeps Overweight Rating	02-26	MT
Evercore ISI Adjusts Price Target on Health Catalyst to $10 From $11, Maintains Outperform Rating	02-23	MT
Canaccord Genuity Trims Price Target on Health Catalyst to $11 From $12, Maintains Buy Rating	02-23	MT
Guggenheim Upgrades Health Catalyst to Buy From Neutral, Price Target is $14	01-26	MT
Evercore ISI Upgrades Health Catalyst to Outperform From In-Line, Raises Price Target to $11 From $9	01-03	MT
Piper Sandler Adjusts Health Catalyst Price Target to $12 From $11, Maintains Overweight Rating	12-22	MT
JPMorgan Upgrades Health Catalyst to Overweight From Neutral, Cuts Price Target to $11 From $14	12-13	MT
Piper Sandler Upgrades Health Catalyst to Overweight From Neutral, Trims Price Target to $11 From $12	11-13	MT
RBC Cuts Price Target on Health Catalyst to $8 From $13, Keeps Sector Perform Rating	30/10/23	MT
Canaccord Genuity Adjusts Health Catalyst's Price Target to $14 From $16, Keeps Buy Rating	29/08/23	MT
Cantor Fitzgerald Initiates Health Catalyst at Overweight Rating With $16 Price Target	01/08/23	MT
Guggenheim Downgrades Health Catalyst to Neutral From Buy	10/05/23	MT
RBC Cuts Price Target on Health Catalyst to $13 From $15, Maintains Sector Perform Rating	10/05/23	MT
KeyBanc Upgrades Health Catalyst to Overweight From Sector Weight, Sets Price Target at $16, Cites Early Signs of Improvement in Hospital End Markets	20/04/23	MT
Wells Fargo Upgrades Health Catalyst to Overweight From Equalweight, Adjusts Price Target to $16 From $13	04/04/23	MT
Citigroup Adjusts Health Catalyst Price Target to $16 From $17, Maintains Buy Rating	24/03/23	MT
Citigroup Adjusts Price Target on Health Catalyst to $17 From $16, Keeps Buy Rating	08/03/23	MT
Wells Fargo Adjusts Price Target on Health Catalyst to $13 From $11, Keeps Equalweight Rating	07/03/23	MT
Raymond James Adjusts Price Target on Health Catalyst to $18 From $15, Maintains Strong Buy Rating	02/03/23	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Health Catalyst, Inc.

Equities

HCAT

US42225T1079

Analyst Reco.

Filters